


Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A method for deterring, inhibiting or reversing stenosis, restenosis or unwanted proliferation of an artery in a human or veterinary patient, said method comprising the step of:

administering to the patient a compound having the structural formula



Wherein,

X, Y and Z are same or different and are independently selected from CH₂, O, S, NR₁, N=CH, CH=N and R₂-C=C-R₃, where R₂ and R₃ are H or may combine to form a saturated or unsaturated carbocyclic or heterocyclic ring, optionally substituted with one or more R groups;

R₁ is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl and aroyl, optionally substituted with hydroxy, amino, substituted amino, cyano, alkoxy, halogen, trihaloalkyl, nitro, thio, alkylthio, carboxy and alkoxycarbonyl groups;

R is selected from H, halogen, trihaloalkyl, hydroxy, acyloxy, alkoxy, alkenyloxy, thio, alkylthio, nitro, cyano, ureido, acyl, carboxy, alkoxycarbonyl, N-(R₄)(R₅) and saturated or unsaturated, chiral or achiral, cyclic or acyclic, straight or branched hydrocarbyl group with from 1 to 20

carbon atoms, optionally substituted with hydroxy, halogen, trihaloalkyl, alkylthio, alkoxy, carboxy, alkoxy carbonyl, oxoalkyl, cyano and $N-(R_4)(R_5)$ group,

R_4 and R_5 are selected from H, alkyl, alkenyl, alkynyl, cycloalkyl and acyl or R_4 and R_5 may combine to form a ring, wherein a carbon may be optionally substituted by a heteroatom selected from O, S or N- R_6 ,

R_6 is H, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl or carboxyalkyl,

n is 1-5; m is 1 or 2; with the proviso that

when m is 1, Q is selected from OH, CN, carboxyalkyl, $N-(R_7)(R_8)$, where R_7 and R_8 are selected from H, lower alkyl (1-4C), cycloalkyl, aryl, acyl, amido, or R_7 and R_8 may combine to form a saturated or unsaturated heterocyclic ring and optionally substituted with up to 3 additional heteroatoms selected from N, O, and S; or

-NH-heterocycle, where the heterocycle is represented by thiazole, oxazole, isoxazole, pyridine, pyrimidine, and purine and



where U and V are selected from H and O; and

when m is 2, Q is a spacer of from 2-10 carbons as a straight or branched, chiral or achiral, cyclic or acyclic, saturated or unsaturated, hydrocarbon group, such as phenyl.

In the most preferred embodiment of this invention,

X, Y, and Z are $R_2-C=C-R_3$, where R_2 and R_3 are H;

R is selected from H and halogen, preferably, F and Cl;

m is 1; and

Q is $-N-(R_7)(R_8)$, where R_7 and R_8 are selected from H, acyl, amido, and R_7 and R_8 combine to form a saturated or unsaturated heterocyclic ring, optionally substituted with up to three heteroatoms selected from N, O, or S, for example, pyrrolidine, piperidine, pyrazole, imidazole,

oxazole, isoxazole, tetrazole, azepine, etc., which may be optionally substituted with a lower alkyl or amino group;

wherein the compound is administered at a dose that effectively deters, inhibits or reverses stenosis, restenosis or unwanted proliferation of an artery but does not inhibit hepatic cytochrome P450 enzyme activity.

2. (Previously Presented) A method according to Claim 1 wherein the X, Y, and Z are each $R_2-C=C-R_3$; R_2 and R_3 are H; R is selected from H and halogen m is 2; and Q is a spacer of from 2-10 carbons either as a straight or branched hydrocarbon chain or as a containing a hydrocarbon ring.

3. (Original) A method according to Claim 1 wherein the compound is 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrazole.

4. (Original) A method according to Claim 1 wherein the compound is 1-[(2-fluorophenyl)diphenylmethyl]-1*H*-pyrazole.

5. (Original) A method according to Claim 1 wherein the compound is 1-[(4-chlorophenyl)diphenylmethyl]-1*H*-pyrazole.

6. (Original) A method according to Claim 1 wherein the compound is 1-[(2-fluorophenyl)diphenylmethyl]-1*H*-pyrazole .

7. (Original) A method according to Claim 1 wherein the compound is 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-1,2,3,4-tetrazole.

8. (Original) A method according to Claim 1 wherein the compound is administered to the patient orally.

9. (Original) A method according to Claim 1 wherein the compound is administered to the patient by injection.

10. (Original) A method according to Claim 1 wherein the compound is administered to the patient transdermally.

11. (Original) A method according to Claim 1 wherein the compound is administered to the patient transmucosally.

12. (Original) A method according to Claim 1 wherein the compound is on or in an implantable device and wherein the compound is administered to the patient by implanting the device within the patient's body such that the compound elutes from the implanted device.

13. (Original) A method according to Claim 12 wherein the device comprises a stent.

14. (Original) A method according to Claim 13 wherein the stent is implanted in an artery of the patient such that a therapeutically effective amount of the compound elutes from the stent and deters reocclusion of the artery in which the stent is implanted.

15. (Original) A method according to Claim 13 wherein the stent is implanted in a coronary artery of the patient such that a therapeutically effective amount of the compound elutes from the stent and deters reocclusion of the coronary artery in which the stent is implanted.

16. (Original) A method according to Claim 1 wherein the compound is administered to a patient who has undergone or will undergo an angioplasty, atherectomy and/or stent implantation to treat an occluded blood vessel and wherein the compound is administered in an amount and by a route of administration that is effective to deter reocclusion of the blood vessel.

17-46. (Cancelled)